The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors

Immune checkpoint inhibitors have revolutionised cancer therapeutics. Translational research evaluating the role of biomarkers is essential to identify the ideal target population for these drugs. From a regulatory perspective, the identification of biomarkers and diagnostic assays is strongly encou...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo-Fernandez, I., Delgado, J., Moscetti, L., Sarac, S.B., Zander, H., Mueller-Egert, S., Dunder, K., Pean, E., Bergmann, L., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910722/
https://www.ncbi.nlm.nih.gov/pubmed/33399074
http://dx.doi.org/10.1016/j.esmoop.2020.100008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910722/
https://www.ncbi.nlm.nih.gov/pubmed/33399074
http://dx.doi.org/10.1016/j.esmoop.2020.100008

Ejemplares similares